Drug treatment of scleroderma

Drugs

Volumn 61, Issue 3, 2001, Pages 419-427

  Leighton, Carol ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ASCORBIC ACID; CALCIUM ANTAGONIST; CISAPRIDE; CYCLOPHOSPHAMIDE; DIGOXIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EMOLLIENT AGENT; ENALAPRIL; FLUOXETINE; GLYCERYL TRINITRATE; ILOPROST; IMMUNOGLOBULIN; KETANSERIN; LOSARTAN; METHOTREXATE; NIFEDIPINE; PENICILLAMINE; PREDNISOLONE; PROSTACYCLIN; PROTON PUMP INHIBITOR; SEROTONIN UPTAKE INHIBITOR; THYMOCYTE ANTIBODY; TOCOPHEROL; UNINDEXED DRUG; VASODILATOR AGENT;

CLINICAL TRIAL; FIBRIN DEPOSITION; GASTROINTESTINAL DISEASE; HEART DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; LUNG FIBROSIS; MUSCULOSKELETAL DISEASE; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; REVIEW; SCLERODERMA; SKIN DISEASE;

SCLERODERMA;

EID: 0035064889     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200161030-00008     Document Type: Review

References (42)

1. ABC of rheumatology: Raynaud's phenomenon, scleroderma and overlap syndromes
2. The management of systemic sclerosis
3. Immunologic aspects of scleroderma
4. Mortality in systemic sclerosis (scleroderma)
5. Prevalence of Raynaud's phenomenon in the general population: A preliminary study by questionnaire
6. The clinical significance of Raynaud's syndrome
7. Pharmacotherapy of Raynaud's phenomenon
8. A randomised double-blind trial of diltiazem in the treatment of Raynaud's phenomenon
9. The treatment of severe Raynaud's phenomenon with verapamil
10. A controlled trial of the effect of topical glyceryl trinitrate on skin blood flow and skin elasticity in scleroderma
11. International study of ketanserin in Raynaud's phenomenon
12. Ketanserin for Raynaud's phenomenon in progressive systemic sclerosis [computer file]
13. The effects of thromboxane A2 inhibition (picotamide) and angiotensin II blockade (losartan) in primary Raynaud's phenomenon
14. The pharmacological effects of cicaprost, an oral prostacyclin analogue, in patients with Raynaud's syndrome secondary to systemic sclerosis a preliminary study
15. Oral iloprost for Raynaud's phenomenon
16. Gastrointestinal features of scleroderma
17. Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis with interstitial lung disease
18. Intravenous cyclophosphamide pulse therapy for the treatment of lung disease associated with scleroderma
19. The effect of high doses of calcium channel-blockers on survival in primary pulmonary hypertension
20. Survival in patients with primary pulmonary hypertension: Results from a national prospective registry
21. Short- and long-term hemodynamic effects of captopril in patients with pulmonary hypertension and selected connective tissue disease
22. Increased serum angiotensin I converting enzyme activity in patients with mixed connective tissue disease and pulmonary hypertension
23. Intravenous iloprost in patients with Raynaud's phenomenon secondary to systemic sclerosis: A multicentre, placebo-controlled, double-blind study
24. Acomparison of continuous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension: The primary pulmonary hypertension study group
25. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol): Results of a randomised trial
26. Treatment of primary pulmonary hypertension with intravenous epoprostenol (prostacyclin)
27. Long-term iloprost infusion therapy for severe pulmonary hypertension in patients with connective tissue diseases
28. Calcitonin gene-related peptide and its receptors: Molecular genetics, physiology, pathophysiology and therapeutic potentials
29. Calcitonin gene-related peptide in treatment of severe peripheral vascular insufficiency in Raynaud's phenomenon
30. Prolonged effect of CGRP in Raynaud's patients: A double-blind randomised comparison with prostacyclin
31. Beneficial effects of antithymocyte globulin in severe cases of progressive systemic sclerosis
32. Pilot study of antithymocyte globulin in systemic sclerosis
33. Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide
34. Visceral improvement following combined plasmapheresis and immunosuppressive drug therapy in progressive systemic sclerosis
35. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: A 24 week randomised double-blind trial, followed by a 24 week observational trial
36. Cyclosporin in successful control of rapidly progressive scleroderma
37. Acute renal failure occurring in scleroderma treated with cyclosporin A: A report of three cases
38. Case control study of corticosteroid use prior to scleroderma renal crisis
39. D-penicillamine therapy in progressive systemic sclerosis (scleroderma): A retro-spective analysis
40. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: Analysis of a two year, double-blind, randomised, controlled clinical trial
41. Recombinant human relaxin in the treatment of scleroderma: A randomised, doubleblind, placebo-controlled trial
42. Choosing appropriate patients with systemic sclerosis for treatment by autologous stem cell transplantation